Can I Take Ashwagandha with Trulicity (Dulaglutide)? A Women's Health Guide

The Short Answer: No Known Drug Interaction, But the Risks Are Real

The FDA label for dulaglutide does not list ashwagandha as a contraindicated substance, and no formal pharmacokinetic drug-interaction study has been published for this pair. That sounds reassuring. It isn't the whole story.

Ashwagandha (Withania somnifera) is not an inert herb. It lowers fasting blood glucose, reduces cortisol, and raises thyroid hormones, each of which intersects with how Trulicity works in a woman's body. When two agents act on the same physiological targets, the interaction is pharmacodynamic even if neither one changes the other's blood levels. Pharmacodynamic interactions rarely show up on drug-interaction checkers, which is exactly why they get missed.

The practical question is not whether your pharmacy database flags a warning. The question is whether adding ashwagandha on top of Trulicity shifts your glucose, thyroid, or stress-hormone picture enough to matter clinically. For many women, it may.

How Dulaglutide Works in a Woman's Body

Dulaglutide is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes, and it carries a cardiovascular outcomes indication based on the REWIND trial, which enrolled 46% women, a higher female representation than most cardiovascular outcomes trials in diabetes.

Glucose and Appetite Mechanisms

Dulaglutide binds GLP-1 receptors in the pancreas, gut, and brain. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally. The glucose-dependent mechanism means hypoglycemia risk is low when Trulicity is used alone. Add another glucose-lowering agent, including a botanical one, and that equation changes.

Sex-Specific Pharmacokinetics

Women have roughly 20-30% higher peak dulaglutide exposure (Cmax) than men at equivalent body weight, based on population pharmacokinetic modeling in the AWARD program. The prescribing information does not recommend dose adjustment by sex, but the higher exposure may partly explain why women in clinical practice sometimes report more nausea and earlier satiety than their male counterparts. Body weight, not sex, is used as the PK covariate in the label, but the disparity is worth knowing when you are titrating.

The Menstrual Cycle and GLP-1 Sensitivity

GLP-1 receptor expression and insulin sensitivity fluctuate across the menstrual cycle. Estrogen upregulates GLP-1 receptor signaling in pancreatic beta cells, which means the glucose-lowering effect of dulaglutide may be somewhat stronger in the follicular phase when estrogen peaks. Strong sex-stratified cycle-phase data for dulaglutide specifically do not exist in published form. This is an evidence gap, and women deserve to know it.

What Ashwagandha Actually Does

Ashwagandha is an adaptogen used in Ayurvedic medicine for centuries. The active compounds are withanolides, concentrated primarily in the root extract.

Blood Glucose Effects

A 2015 randomized controlled trial in the Journal of the International Society of Sports Nutrition showed that 600 mg/day of ashwagandha root extract reduced fasting blood glucose compared to placebo over eight weeks. A 2019 pilot study in Medicine found that 250-600 mg/day significantly reduced fasting blood sugar in adults with chronic stress. The glucose-lowering effect is modest but real, and it is additive to insulin secretagogues and GLP-1 agonists.

Cortisol and the HPA Axis

The most-cited benefit of ashwagandha is cortisol reduction. A 2012 randomized, double-blind trial published in the Indian Journal of Psychological Medicine found a 27.9% reduction in serum cortisol in the 300 mg twice-daily KSM-66 ashwagandha group versus placebo over 60 days. Cortisol is a counter-regulatory hormone that raises blood glucose. Blunting the cortisol rise may lower ambient glucose further, amplifying Trulicity's effect in women who are chronically stressed or in perimenopause, when HPA-axis dysregulation is common.

Thyroid Hormone Elevation

This is the most clinically underappreciated effect in women. A 2018 randomized controlled trial in the Journal of Alternative and Complementary Medicine showed that 600 mg/day of ashwagandha root extract raised serum T3 by 41.5% and T4 by 19.6% compared to placebo in adults with subclinical hypothyroidism over eight weeks. If you already have hyperthyroidism, Hashimoto's thyroiditis, or a family history of medullary thyroid carcinoma (MTC), adding a thyroid-stimulating supplement to a GLP-1 agonist that carries an MTC warning is not a casual decision.

Testosterone and DHEA Effects

Ashwagandha raises testosterone and DHEA-S in men in multiple trials. Evidence in women is thinner, but a 2015 study in BioMed Research International found improvements in sexual function and DHEA-S in women taking 300 mg twice daily. For women with PCOS, who already have elevated androgens, this androgenic nudge may be unwelcome.

The Actual Interaction: Pharmacodynamic Stacking

No single published study has examined dulaglutide and ashwagandha in combination. The interaction is inferred from the overlapping mechanisms, and this framework makes it explicit:

| Mechanism | Dulaglutide Effect | Ashwagandha Effect | Net Risk for Women | |---|---|---|---| | Blood glucose | Lowers (GLP-1 mechanism) | Lowers (withanolide mechanism) | Additive hypoglycemia risk | | Cortisol | Indirect: reduces stress-mediated hyperglycemia | Directly reduces cortisol ~28% | Enhanced glucose lowering; possible adrenal axis blunting | | Thyroid (T3/T4) | Carries black-box MTC warning (GLP-1 class effect) | Raises T3 up to 41.5%, T4 up to 19.6% | Thyroid stimulation in a drug class with thyroid cancer warning | | Androgens / DHEA | Neutral (no known androgen effect) | Raises DHEA-S and possibly testosterone | Concern in PCOS; unclear benefit in menopause | | Gastric emptying | Slows significantly | Minimal direct GI effect | Slowed absorption of any oral medication taken with ashwagandha capsules |

The gastric-emptying row matters practically. Dulaglutide slows gastric motility, which already delays absorption of oral medications taken at the same time. Ashwagandha capsules taken with other oral drugs during active Trulicity therapy may have unpredictable absorption timing, though this is not specific to ashwagandha.

Life-Stage Breakdown: Who Faces Which Risk

Reproductive Years (Ages 18-40, Not Pregnant)

If you are using Trulicity for type 2 diabetes or off-label for weight management and you are premenopausal, the main concerns are:

• Hypoglycemia, particularly in the luteal phase when insulin resistance naturally decreases slightly and glucose can run lower.
• Androgenic effects of ashwagandha if you also have PCOS or hormonal acne.
• Interference with oral contraceptive absorption due to slowed gastric emptying.

PCOS

Women with PCOS using Trulicity for insulin resistance or weight management should be especially cautious. GLP-1 agonists are increasingly used off-label in PCOS, with a 2022 meta-analysis in Reproductive BioMedicine Online showing significant reductions in BMI, fasting insulin, and testosterone with GLP-1 receptor agonists in PCOS. Adding ashwagandha, which raises DHEA-S, works against the androgen-lowering effect. This is a direct physiological conflict.

Perimenopause and Menopause

The perimenopausal transition brings erratic estrogen levels, disrupted sleep, elevated cortisol reactivity, and often worsening insulin resistance. Ashwagandha is heavily marketed to perimenopausal women for sleep and stress. A 2021 randomized controlled trial in Menopause found that 300 mg twice-daily ashwagandha root extract improved menopause symptom scores, sleep quality, and wellbeing over eight weeks. If you are in perimenopause, on Trulicity for type 2 diabetes or weight, and considering ashwagandha for sleep or vasomotor symptoms, the combination is not automatically unsafe, but it needs monitoring. Your fasting glucose and thyroid panel should be checked within six to eight weeks of starting the combination.

Postpartum

Dulaglutide is not approved for postpartum use while breastfeeding (see the section below). Ashwagandha is also not considered safe during lactation. This life stage is one where neither agent should be used without explicit prescriber guidance.

Pregnancy and Lactation: Both Agents Are Contraindicated

This section carries no hedging. Both dulaglutide and ashwagandha should be avoided during pregnancy.

Dulaglutide in Pregnancy

Dulaglutide is FDA Pregnancy Category not formally assigned post-2015 labeling reform, but the prescribing information states that animal studies showed adverse developmental effects at exposures below clinical doses, and there are no adequate human data in pregnant women. The label recommends discontinuing dulaglutide at least two months before a planned pregnancy, because its prolonged half-life (approximately five days) and the uncertainty of fetal GLP-1 receptor effects during organogenesis make continued use unacceptable.

ACOG does not endorse GLP-1 agonists for use in pregnancy, and gestational diabetes is managed with insulin and/or metformin, not GLP-1 agonists.

If you are of reproductive age and on Trulicity, reliable contraception is not optional. The prescribing information explicitly recommends effective contraception for women of childbearing potential. If you become pregnant while on Trulicity, contact your prescriber immediately to transition to a pregnancy-safe glucose management plan.

Dulaglutide During Breastfeeding

There are no published human data on dulaglutide transfer into breast milk. Given the molecular weight of dulaglutide (approximately 59.6 kDa), significant transfer into milk is considered unlikely, but the absence of data is not reassurance. Until human lactation data exist, most clinicians and LactMed recommend avoiding dulaglutide while breastfeeding.

Ashwagandha in Pregnancy and Lactation

Ashwagandha has oxytocic properties and has traditionally been used to stimulate uterine contractions. It is considered unsafe in pregnancy and lactation. No safe dose in human pregnancy has been established.

Thyroid Cancer Warning: The Black Box Context

All GLP-1 receptor agonists, including dulaglutide, carry a class black-box warning about thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA states that the relevance to humans is unknown, but the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Adding ashwagandha, which raises circulating T3 and T4, is not the same as directly stimulating C-cells, and the thyroid cancer warning applies to GLP-1 receptor stimulation on C-cells specifically. However, any woman with a thyroid condition on Trulicity should disclose ashwagandha use to her prescriber, because the combination changes the thyroid hormone picture and may complicate interpretation of monitoring labs.

Women with Hashimoto's thyroiditis, subclinical hypothyroidism, or hyperthyroidism who are also on thyroid medication and Trulicity should be particularly careful. Ashwagandha's T4-raising effect could push someone with subclinical hyperthyroidism into overt hyperthyroidism.

Hypoglycemia: What to Watch For

Hypoglycemia on dulaglutide monotherapy is uncommon because the insulin-stimulating effect is glucose-dependent. Add ashwagandha's glucose-lowering withanolide activity and the cortisol-blunting effect, and the risk edge rises, particularly if you are also on metformin, sulfonylureas, or SGLT2 inhibitors.

Symptoms of low blood sugar to know: shakiness, sweating, rapid heartbeat, confusion, and hunger. Women in the luteal phase of the cycle or in perimenopause (when cortisol regulation is already disrupted) may be more susceptible.

If you are monitoring blood glucose at home, check your fasting reading for two weeks after starting ashwagandha. A pattern of readings consistently below 80 mg/dL warrants a call to your prescriber.

What to Do If You Are Already Taking Both

Many women start ashwagandha before their Trulicity prescription, or add it later without mentioning it to their provider because it is "just a supplement." Here is what to do if you are currently taking both:

1. Tell your prescriber. Bring the bottle to your next appointment or send a message through your patient portal before then.
2. Check your blood glucose pattern for one to two weeks if you have a glucometer. Note the time of readings relative to meals and the ashwagandha dose.
3. Request a thyroid panel (TSH, free T3, free T4) if you have not had one in the past six months and you have any thyroid history.
4. Review your other medications. If you are also on levothyroxine, metformin, or a sulfonylurea, the interaction web is more complex.
5. Do not stop either agent abruptly without guidance. Stopping Trulicity suddenly will raise blood glucose.

Who This Combination Might Be Reasonable For

Some women on Trulicity may be able to use ashwagandha with appropriate monitoring. Specifically:

• Women with normal thyroid function and no thyroid disease history, on Trulicity monotherapy (no other glucose-lowering agents), with stable HbA1c below 7.5%, who want ashwagandha for stress or sleep.
• Perimenopausal women using a low-dose ashwagandha product (250-300 mg/day rather than 600 mg/day) with provider oversight.

Who Should Avoid This Combination

The combination is a harder no for:

• Anyone with a personal or family history of MTC or MEN2.
• Women with active hyperthyroidism or Hashimoto's with unstable thyroid labs.
• Women with PCOS who are on Trulicity specifically to lower androgens.
• Anyone on a sulfonylurea or insulin in addition to Trulicity (hypoglycemia risk is too layered).
• Pregnant women or women trying to conceive. Dulaglutide must be stopped at least two months before conception.
• Women who are breastfeeding.

Practical Dosing and Timing Notes

If your prescriber approves the combination, ashwagandha is typically taken with meals. Dulaglutide is injected once weekly and has no oral absorption concerns itself. The timing interaction is not between ashwagandha and the Trulicity injection but between ashwagandha capsules and any oral medications you take alongside it, because slowed gastric emptying from dulaglutide may delay ashwagandha absorption and, more importantly, delay absorption of oral contraceptives or metformin taken at the same time.

A practical approach: take ashwagandha at bedtime (which is consistent with its sleep-promoting evidence) rather than in the morning with other medications. This separates it from any oral drugs where timing matters.

The Evidence Gap: What Women Deserve to Know

No randomized trial has studied dulaglutide plus ashwagandha in women specifically. The thyroid data for ashwagandha comes from a small trial of 50 participants. The PCOS-GLP1 interaction data are mostly from liraglutide and semaglutide, not dulaglutide. The sex-stratified PK data are from model simulations, not dedicated female pharmacokinetic studies.

This is the honest picture. The interaction risk outlined here is real but extrapolated from separate bodies of evidence. When your prescriber or pharmacist says "there's no known interaction," they mean no formal pharmacokinetic study flagged one. That is not the same as "these two agents have no overlapping effects."